Association between serum lipoprotein-associated phospholipase A2, ischemic modified albumin and acute coronary syndrome: a cross-sectional study
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a newly emerging biomarker with strong pro-inflammatory effects, and is an independent risk predictor of atherosclerotic plaque rupture and thrombosis. In addition, ischemic modified albumin (IMA) is another important marker for the evaluation of myocardial ischemia, and has been approved by the U.S. Food and Drug Administration. The objective of this study was to investigate serum Lp-PLA2 and IMA in the early diagnosis, progression and prognosis of acute coronary syndrome (ACS). Serum Lp-PLA2 and IMA were detected using an AU5800 automatic biochemical analyzer in samples from 180 patients with ACS [n = 60 with unstable angina pectoris (UA), n = 56 with non-ST segment elevation myocardial infarction (NSTEMI), and n = 64 with ST segment elevation myocardial infarction (STEMI)] and 60 healthy control subjects. The relationship between Lp-PLA2 and IMA with Gensini score and the number of coronary artery lesions was explored, and logistic regression was conducted to identify risk factors for major adverse cardiovascular events (MACE). Serum Lp-PLA2 and IMA were significantly higher in all ACS subgroups compared to the control group (P < 0.05), were positively associated with the severity of ACS based on the Gensini score (P < 0.05), and were significantly higher in patients with double- and triple-vessel lesions compared to those with single-vessel lesions and healthy controls (P < 0.05). Logistic regression identified Lp-PLA2, IMA, and troponin I levels as independent risk factors for MACE. Lp-PLA2 and IMA were predictive of the degree of myocardial ischemia in patients with ACS, and may provide important clinical significance for the early diagnosis of ACS and the choice of treatment strategy.
KeywordsAcute coronary syndrome Lipoprotein-associated phospholipase A2 Ischemia-modified albumin Gensini score Major adverse cardiovascular events
Acute coronary syndrome
High-density lipoprotein cholesterol
Ischemic modified albumin
Low-density lipoprotein cholesterol
Lipoprotein-associated phospholipase A2
Major adverse cardiovascular events
Non-ST segment elevation myocardial infarction
Percutaneous coronary intervention
ST segment elevation myocardial infarction
Unstable angina pectoris
FY and QL conceived and designed the experiments. LZ, YW, and CZ performed the experiments. WZ, WL and LM analyzed the data. FY, LM, and QL wrote or revised the manuscript. All the authors approved the final submitted version of the manuscript.
Research projects of Bengbu Medical College (BYKY17184, 18178), Young and Middle-aged Talents Growth Foundation of the Second People’s Hospital of Lianyungang (TQ201709), and Health Scientific Research Project in Lianyungang (201721, 201817).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest with this work.
- 1.Emergency Medical Branch of Chinese Mdical Doctor Association, Cardiovascular Epidemiology Branch of Chinese Medical Association, Laboratory Medicine Branch of Chinese Medical Association (2016) Emergency rapid diagnosis and treatment of guidelines acute coronary syndrome. Chin J Emerg Med 25:397–404Google Scholar
- 6.Ge PC, Chen ZH, Pan RY, Ding XQ, Liu JY, Jia QW, Liu Z, He SZ, An FH, Li LH, Li ZY, Gu Y, Zhu TB, Li CJ, Wang LS, Ma WZ, Yang ZJ, Jia EZ (2016) Synergistic effect of lipoprotein-associated phospholipase A2 with classical risk factors on coronary heart disease: a multi-ethnic study in China. Cell Physiol Biochem 40:953–968CrossRefGoogle Scholar
- 13.Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM, Naidu SS, Ohman EM, Smith PK (2014) 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 64:1929–1949CrossRefGoogle Scholar
- 14.O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61:485–510CrossRefGoogle Scholar
- 15.Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ, ACC/AHA Task Force Members; Society for Cardiovascular Angiography, and Interventions, and the Society of Thoracic Surgeons (2014) 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 130:2354–2394CrossRefGoogle Scholar
- 17.Chen PM, Ohno M, Hiwasa T, Nishi K, Saijo S, Sakamoto J, Morita Y, Matsuda S, Watanabe S, Kuwabara Y, Ono K, Imai M, Inoue K, Murai T, Inada T, Tanaka M, Kita T, Kimura T, Nishi E (2017) Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Int J Cardiol 243:1–8CrossRefGoogle Scholar
- 18.Younus A, Humayun C, Ahmad R, Ogunmoroti O, Kandimalla Y, Aziz M, Malik R, Saand AR, Valdes C, Badlani R, Younus MA, Ali SS, Chen Y, Nasir K (2017) Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. J Clin Lipidol 11:328–337CrossRefGoogle Scholar
- 19.De Mauri A, Vidali M, Chiarinotti D, Bellomo G, Rolla R (2018) Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients. J Nephrol doi: 10.1007/s40620-018-0521-3Google Scholar
- 21.Lu J, Niu D, Zheng D, Zhang Q, Li W (2018) Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk. Biomed Rep 9:517–522Google Scholar
- 24.Demir MT, Baydin A, Amanvermez R, Erenler AK, Güzel M, Yücel O (2018) Comparison of pentraxin-3 and ischemia-modified albumin with troponin in early diagnosis of acute coronary syndrome. Bratisl Lek Listy 119:509–512Google Scholar
- 25.Turan T, Akyüz AR, Sahin S, Kul S, Yilmaz AS, Kara F, Mentese SO, Aykan AÇ, Demir S, Celik S, Karahan SC (2017) Association between the plasma levels of IMA and coronary atherosclerotic plaque burden and ischemic burden in early phase of non-ST-segment-elevation acute coronary syndromes. Eur Rev Med Pharmacol Sci 21:576–583Google Scholar